Asset
Duvalgagene Otiparvovec
4D Molecular Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05629559 | phase1_2 | recruiting | 2022-10-16 | 2026-06-01 | 4D Molecular Therapeutics | 4D-310 in Adults With Fabry Disease and Cardiac Involvement |
| NCT04519749 | phase1_2 | active_not_recruiting | 2020-09-01 | 2026-01-01 | 4D Molecular Therapeutics | An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease |
FDA applications (0)
This company has no applications containing this asset.